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doi:10.1016/j.ejvs.2008.01.021Abstract Objective: Although systemic heparinisation is routine during CEA, reversal with
protamine is controversial with 3 studies suggesting increased peri-operative stroke rates
and 3 no effect. None included independent peer-review.
Design: Non-randomised observational study of data derived from a randomised controlled
study of anaesthetic technique for CEA.
Methods: Data on heparin and protamine use and risk factors potentially influencing CEA out-
come were collected prospectively. Stroke, death, MI, wound haematoma and re-operation
rates were recorded following independent peer-review.
Results: 1513/2107 patients received heparin alone (H) and 594/2107 had heparin reversed
with protamine (HþP). Risk factors for outcome were similar in both groups. The frequency
of outcome events (H v HþP) were: stroke: 67/1513 (4.4%) v 17/594 (2.9%), pZ 0.098; non
stroke or MI death: 10/1513 (0.7%) v 5/594 (0.8%), pZ 0.657; MI: 6/1513 (0.4%) v 3/594
(0.5%), pZ 0.718; haematoma: 157/1513 (10.4%) v 44/594 (7.4%), pZ 0.037; re-operation:
51/1380 (3.7%) v 18/565 (3.2%), pZ 0.581.
Conclusions: These results show a non-significant increase in stroke rate in patients receiving
heparin alone refuting suggestions that protamine is harmful. Conversely post-operative
haematoma was more frequent when protamine was withheld but re-operation rates were
no different. Thus protamine use appears safe and should remain a matter for individual
surgeon preference.
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Administration of heparin to achieve a systemic antico-
agulation prior to application of the vascular clamps during
carotid endarterectomy is routine. However its subsequentd by Elsevier Ltd. All rights reserved.
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decision to use protamine depends on the perceived risk
of bleeding from the wound or suture line and subsequent
haematoma formation, against the potential risk of
promoting thrombosis at the endarterectomy site and
ischaemic stroke. Other side-effects of protamine use
(anaphylaxis, transient hypotension, pulmonary hyperten-
sion) are rare and appear to be related to the much higher
doses of the drug that are given following cardio-pulmonary
bypass.
Three studies have associated the use of protamine with
an increased stroke risk. The randomised prospective study
by Fearn et al.,1 whilst investigating the effect of prot-
amine on the development of wound haematoma noted 2
strokes in the patients receiving protamine and none in
those who did not. The study was discontinued early after
recruiting 63 patients. This was prompted in part by the
publication of a retrospective study of 348 patients2 which
reported a significantly increased risk of stroke when prot-
amine was given. A further retrospective study by Levison
et al3 also suggested an association between protamine
and stroke risk, although no statistical significance was
demonstrated. Stroke risk notwithstanding, the study by
Fearn et al1 demonstrated a significant decrease in wound
drainage with protamine use and that of Levison et al3
identified a significant reduction in the incidence of wound
haematoma. Treiman et al,4 in another retrospective study,
found a significant reduction in haematoma rates without
associated stroke risk. Two further retrospective studies
from the USA reporting on the association of processes of
care with outcome following carotid endarterectomy did
not find an association between protamine use and adverse
outcome.5,6
In an attempt to clarify the role of protamine in CEA, the
effect of its use on outcome was examined in an analysis of
data from 2158 patients participating in the ongoing GALA
Trial, a multicentre prospective randomised trial of general
(GA) versus local (LA) anaesthesia in carotid
endarterectomy.Table 1 Comparison of demographic characteristics and
indication for surgery
Protamine No Protamine p value
Age in years (mean) 70.0 70.4 0.335y
Median (IQR) 71.0
(64.0e76.0)
71.5
(64.6e76.9)
Sex
Male 403 1067 0.229*
Female 191 446
% ipsilateral carotid stenosis
Median (IQR) 80.0
(75.0e90.0)
84.5
(75.0e90.0)
0.029y
% contralateral carotid stenosis
Median (IQR) 40.0
(10.0e67.5)
40.0
(0.0e70.0)
0.860y
Contralateral
occlusion (%)
58 (9.8) 152 (10.1) 0.846*
Asymptomatic (%) 255 (42.9) 418 (27.6) <0.001*
* chi-squared test.
y Mann-Whitney U test.Methods
In the GALA Trial w(multicentre international randomised
trial of general versus local anaesthetic for carotid endar-
terectomy) centres perform CEA according to their normal
practice; the Trial is prescriptive only in that the use of
a shunt in patients randomised to receive LA should be
determined by awake neurological testing.
Data regarding demographics, indication for surgery and
details of each procedure were collected prospectively.
The 30-day outcome was independently assessed by a stroke
physician or neurologist. Data on the main outcome events,
including stroke, death, myocardial infarction, haematoma
and re-operation were forwarded to the Trial office.
Unblinded data (excluding the type of anaesthetic and
shunt use) was provided for this study. Statistical analysis
was performed using the chi-squared test (or Fisher’s exact
test for small samples where appropriate) for nominal data
and the Mann-Whitney U test for non-normal distributions
of continuous data, using a proprietary statistics software
package (SPSS 12.0.1). Multivariable logistic regression wasperformed using SAS version 9.1.3, with all variables of
interest being added to the model concurrently.
Results
Of 2158 randomised patients, 2107 received heparin, of
whom 594 had this reversed with protamine. Demographic
details and the indication for surgery for each group are
shown in Table 1. Details of surgery are shown in Table 2.
The groups were well matched for age, sex, endarter-
ectomy technique, patch use, duration of surgery, grade of
operating surgeon and severity of contralateral carotid
stenosis. The severity of the ipsilateral stenosis (assessed
primarily by duplex ultrasound based on NASCET criteria)
was greater in patients who did not receive protamine
(median IQR: 84.5% (75.0e90.0) v 80.0% (75.0e90.0),
pZ 0.029 and there were more asymptomatic patients in
the protamine group (255/594 v 418/1513 p< 0.001).
The stroke rate in the protamine group was 2.9%,
compared to 4.4% in the group receiving heparin only
(Table 3). This difference was not statistically significant,
and the effect remained in the same direction, and non-
statistically significant after adjusting for potential
confounding variables (Table 4). Similarly protamine admin-
istration had no impact on non-stroke or MI death, MI, and
re-operation rates (Table 3) but was associated with a lower
frequency of wound haematoma (7.4% vs. 10.4% pZ 0.037).
Data regarding the precise dose of heparin and prot-
amine was available in 1824/2107 (86.6%) and 519/594
(87.4%) patients respectively; the median dose of heparin
was 5000 iu (IQR 3000e5000) whilst that of protamine was
25 mg (IQR 15e50 mg). Patients who had a stroke (69/1824)
received a lower median dose of heparin (4000 iu [3000e
5000] vs. 5000 iu [3000e5000], pZ 0.026), whilst those
requiring re-operation (17/491) had received a lower dose
Table 2 Comparison of details of procedure
Protamine No protamine p value
Type of surgery (%)
(nZ 1835)
Conventional 408 (78.4) 1053 (80.1) 0.438*
Eversion 104 (20.0) 250 (19.0)
Other 8 (1.5) 12 (0.9)
Grade of surgeon (%)
Consultant 510 (85.9) 1257 (83.1) 0.119*
Trainee 84 (14.1) 256 (16.9)
Use of patch (%) 296 (50.0) 699 (46.5) 0.146*
Duration of
surgery (mean)
96.2 min 94.7 min 0.860y
Median (IQR) 90.0
(70.0e113.5)
90.0
(70.0e120.0)
* chi-squared test.
y Mann-Whitney U test.
Table 3 Summary of major outcome data
Protamine No Protamine p value
Stroke or Retinal
Infarction (%)
17 (2.9) 67 (4.4) 0.098*
Non-stroke
death (%)
5 (0.8) 10 (0.7) 0.657*
Myocardial
infarction (%)
3 (0.5) 6 (0.4) 0.718y
Stroke, Death
or MI (%)
25 (4.2) 83 (5.5) 0.232*
Haematoma (%) 44 (7.4) 157 (10.4) 0.037*
Re-operation (%) 18 (3.2) 51 (3.7) 0.581*
* chi-squared test.
y Fisher’s Exact test.
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v 25 mg [15e50], pZ 0.046, Mann-Whitney U test).
Discussion
Although this is not a randomised study assessing the risks
and benefits of protamine use during carotid endarterec-
tomy, it is a large observational study of patients
undergoing surgery in Europe during the last 5 years. Thus
we believe that the results are applicable to current
practice. Further, the occurrence of stroke, death and MI
were monitored by an independent neurologist, which adds
further weight to the validity of these results.
We have found no association between the use of
protamine and serious adverse events. In particular, stroke
rates were slightly lower in patients receiving protamine.
This group also had a significant reduction in the frequency
of wound haematoma. These data challenge earlier sug-
gestions that protamine increases the thromboembolic
complications of carotid endarterectomy1e3 and is in agree-
ment with data from the USA which reported no association
between protamine administration and an adverse out-
come.5,6 Further, it should be noted that the studies report-
ing an adverse effect of protamine were flawed forTable 4 The relationship between stroke outcome and protamin
ables using multivariable logistic regression analysis
Variable Stroke
(NZ 84)
Protamine used (N and %) 17 (20%)
Heparin dose [IU]
(mean and s.d.)
4486 (2494)
Age (mean and s.d.) 70.5 (8.5)
% contralateral carotid stenosis
(mean and s.d.)
82.9 (10.7)
Duration of surgery in minutes
(mean and s.d.)
94.2 (40.4)
Asymptomatic (N and %) 16 (19%)a number of reasons. The studies by Mauney et al2 and
Levison et al3 were both retrospective historical studies in
single-centre institutions. Mauney et al,2 whilst showing
a statistically significant increase in stroke rate associated
with protamine use, reported only 5 strokes in 348 patients,
and acknowledged the limited statistical power of their
findings. Similarly Levison et al3 reported only 10 strokes
out of 407 CEAs, and their suggestion of increased risk
with protamine use failed to reach statistical significance.
The study by Fearn et al,1 although prospective and rando-
mised, was also small (only 64 CEAs). It showed a non-
significant risk of ICA thrombosis with protamine use
although interestingly, in these patients a patch was used
less often. Finally, none of these studies employed inde-
pendent postoperative assessment of patients by a stroke
physician or neurologist.
Because this is a non-randomised study some inconsis-
tencies are inevitable. Thus, surgery for an asymptomatic
stenosis was more common in the group receiving
protamine and, as expected, stroke rates were lower in
asymptomatic compared to symptomatic patients in the
study as a whole (2.4% vs 4.7% pZ 0.01 chi-squared test).
The impact of this on the results has been assessed by
multivariate analysis of potential confounding variables
(Table 4). In contrast, other factors that might influence
the outcome of surgery (type of surgery, duration of sur-
gery, patch use, grade of surgeon, contralateral occlusion)e use with adjustment for other potentially confounding vari-
No Stroke
(NZ 2023)
Odds ratio (95%
confidence interval)
Wald
p value
577 (29%) 0.79 (0.40, 1.56) 0.505
4992 (2890) 1.00 (1.00, 1.00) 0.538
70.3 (8.8) 0.99 (0.97, 1.02) 0.741
81.6 (10.3) 1.01 (0.99, 1.04) 0.269
95.1 (34.8) 1.00 (0.99, 1.01) 0.988
657 (32%) 0.51 (0.28, 0.93) 0.027
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heparinþ protamine groups (Table 2).
Although protamine use did not impact on stroke, MI and
death rates its omission did increase the incidence of
wound haematoma (Table 3) although this was not
reflected by an increased need for re-operation. Whilst
a strict definition of haematoma was not used, the need
for re-operation is more likely to be of clinical relevance.
The influence, if any, of pre-operative antiplatelet drugs
on wound haematoma rates has not been assessed since
this data was not collected during the pilot phase of the
Trial when approximately 700 of these patients were
recruited.
It is not known whether the study groups were equally
matched for the use of a shunt. This data was not made
available for the analysis due to the concern that it might
partially unblind the allocation of anaesthesia, especially in
centres which routinely shunted during GA. Nevertheless
a recent meta-analysis has failed to identify a relationship
between a policy of never, selectively or routinely shunting
and the risk of stroke during CEA.7
In conclusion this study shows no association between
the use of protamine and adverse outcome following
carotid endarterectomy. These findings should reassure
surgeons who use protamine during surgery that it appears
safe to do so.
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